1. Home
  2. CMCO vs LCTX Comparison

CMCO vs LCTX Comparison

Compare CMCO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Columbus McKinnon Corporation

CMCO

Columbus McKinnon Corporation

HOLD

Current Price

$17.05

Market Cap

430.3M

Sector

Industrials

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.75

Market Cap

393.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMCO
LCTX
Founded
1875
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
430.3M
393.9M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CMCO
LCTX
Price
$17.05
$1.75
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$35.00
$4.25
AVG Volume (30 Days)
258.9K
2.2M
Earning Date
10-30-2025
11-06-2025
Dividend Yield
1.64%
N/A
EPS Growth
N/A
N/A
EPS
0.13
N/A
Revenue
$977,994,000.00
$10,816,000.00
Revenue This Year
$5.60
$5.24
Revenue Next Year
$4.23
$126.78
P/E Ratio
$129.86
N/A
Revenue Growth
N/A
24.05
52 Week Low
$11.78
$0.37
52 Week High
$41.05
$2.09

Technical Indicators

Market Signals
Indicator
CMCO
LCTX
Relative Strength Index (RSI) 63.75 50.96
Support Level $16.16 $1.57
Resistance Level $16.56 $1.76
Average True Range (ATR) 0.63 0.11
MACD 0.21 -0.01
Stochastic Oscillator 88.41 44.16

Price Performance

Historical Comparison
CMCO
LCTX

About CMCO Columbus McKinnon Corporation

Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: